FDA Approves KEYTRUDA® as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB, II, or IIIA NSCLC February 1, 2023
Pivotal LUNAR Study of TTFields + SoC in NSCLC Met Primary Overall Survival Endpoint January 11, 2023
FAILED TRIAL: PEARL Ph 3 trial for Imfinzi (durvalumab) monotherapy did not achieve statistical significance of improving OS vs chemo as a monotherapy treatment in PD-L1+ve mNSCLC patients January 4, 2023
Safety Review Committee Approves to Proceed to Final Cohort in Acclaim-1 Ph 1 Dose Escalation Trial of REQORSA® + Tagrisso® in Advanced NSCLC December 19, 2022
U.S. FDA announces Accelerated Approval of KRAZATI™ (adagrasib) for Patients with Locally Advanced or Metastatic NSCLC with a KRASG12C Mutation December 19, 2022
Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody Ivonescimab December 13, 2022
Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration December 13, 2022
PERLA Ph 2 trial of Jemperli (dostarlimab) plus chemotherapy shows positive results in 1L mNSCLC December 12, 2022
FAILED TRIAL: Ph 3 CONTACT-01 trial of cabozantinib + atezolizumab in IO- and chemo-treated mNSCLC patients did not meet its primary endpoint of OS December 12, 2022
SAPPHIRE Ph 3 study of sitravatinib + nivolumab in patients with chemo- and IO-resistant 2L/3L NSQ-NSCLC will continue to the study’s final analysis December 5, 2022
Lyvgen Announces Ph 2 Clinical Collaboration with Bristol Myers Squibb to Evaluate LVGN7409 in Combination with Nivolumab in NSCLC Patients November 30, 2022
Positive Update On Joint TIGIT Program From Interim Analysis Of ARC-7 Study In NSCLC Announced November 30, 2022
Durable Responses of Botensilimab/Balstilimab Combination in Nine Different Treatment-Resistant Cancers announced November 23, 2022
Incyte And Mirati Therapeutics Enter To Evaluate INCB99280 And Adagrasib In Patients With KRASG12C-Mutated Solid Tumors November 16, 2022
Promising SRF388 Monotherapy Data in NSCLC announced, Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort November 16, 2022
Imfinzi and Imjudo with chemotherapy approved in the US for patients with mNSCLC based on POSEIDON Phase III trial results November 16, 2022
FDA approves cemiplimab (Libtayo) with platinum-based chemotherapy for the treatment of advanced NSCLC patients with WT EGFR, ALK, or ROS1 November 16, 2022
Updated Findings from the Ph 2 SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC Presented November 4, 2022
Preliminary Ph 1 Clinical Data from ARROS-1 Trial of NVL-520 for Patients with ROS1-Positive NSCLC reported November 4, 2022
Mirati Therapeutics & Aadi Bioscience Partner to Evaluate Adagrasib + Nab-sirolimus in Advanced NSCLC and Other Solid Tumors patients with a KRAS[G12C] Mutation October 19, 2022
US FDA grants Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with LUMAKRAS® (sotorasib) October 19, 2022
PERLA Ph 2 trial Of Jemperli (Dostarlimab) + Chemotherapy In Patients With mNSCLC met the primary endpoint of ORR October 12, 2022
FDA grants Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for 1L NSCLC October 12, 2022
TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory NSCLC October 5, 2022
